MARKET

RCKT

RCKT

ROCKET PHARMACEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.83
+1.62
+4.35%
Opening 15:13 07/28 EDT
OPEN
37.69
PREV CLOSE
37.21
HIGH
38.83
LOW
37.64
VOLUME
178.14K
TURNOVER
--
52 WEEK HIGH
67.48
52 WEEK LOW
21.95
MARKET CAP
2.46B
P/E (TTM)
-14.2989
1D
5D
1M
3M
1Y
5Y
74 Biggest Movers From Yesterday
Gainers
Benzinga · 1d ago
WestRock Co. stock outperforms market on strong trading day
marketwatch.com · 1d ago
WestRock Co. stock rises Tuesday, still underperforms market
marketwatch.com · 07/20 21:30
WestRock Co. stock outperforms competitors despite losses on the day
marketwatch.com · 07/19 21:30
Should I Avoid Rocket Pharmaceuticals, Inc. (RCKT)?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds...
Insider Monkey · 07/19 16:08
WestRock Co. stock falls Thursday, underperforms market
marketwatch.com · 07/15 21:30
WestRock Co. stock underperforms Monday when compared to competitors
marketwatch.com · 07/12 21:30
WestRock Co. stock rises Friday, outperforms market
marketwatch.com · 07/09 21:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RCKT. Analyze the recent business situations of ROCKET PHARMACEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RCKT stock price target is 71.90 with a high estimate of 100.00 and a low estimate of 56.00.
EPS
Institutional Holdings
Institutions: 209
Institutional Holdings: 66.52M
% Owned: 104.93%
Shares Outstanding: 63.40M
TypeInstitutionsShares
Increased
73
4.94M
New
25
253.24K
Decreased
52
4.25M
Sold Out
29
1.41M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.42%
Pharmaceuticals & Medical Research
+1.99%
Key Executives
Chairman/Director
Roderick Wong
President/Chief Operating Officer
Kinnari Patel
Chief Executive Officer/Director
Gaurav Shah
Chief Financial Officer
Carlos Garciaparada
Chief Accounting Officer/Vice President - Finance/Controller/Treasurer
John Militello
Other
Jonathan Schwartz
Independent Director
Elisabeth Bjork
Independent Director
Carsten Boess
Independent Director
Pedro Granadillo
Independent Director
Gotham Makker
Independent Director
David Southwell
Independent Director
Naveen Yalamanchi
No Data
About RCKT
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

Webull offers kinds of Rocket Pharmaceuticals Inc stock information, including NASDAQ:RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.